teaser
The UK’s National Institute for Clinical Excellence (NICE) has recommended against using abatacept (Orencia®) to treat people with rheumatoid arthritis, stating that it would not be a cost-effective use of NHS resources. The committee noted in its appraisal consultation document that there were no direct head-to-head comparisons of abatacept with alternative conventional DMARD regimens, TNF blockers or rituximab. The closing date for comments is 23 August 2007 and the second appraisal committee meeting will take place on 12 September 2007.
National Electronic Library for Medicines 2/8/2007
